BioPharma Resources

Investigational drug · Phase 3

HTD1801

Also called: Berberine Ursodeoxycholate

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

0 still active

All registered trials

12

Any phase or sponsor naming "HTD1801"

First trial start

2022

Dec 27, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HTD1801", any sponsor or status.

Conditions studied

As listed on its trial records.

  • T2DM (Type 2 Diabetes Mellitus)
  • Nonalcoholic Steatohepatitis (NASH)
  • Type 2 Diabetes
  • Type 2 Diabetes Mellitus

Approved drugs for the same conditions: Type 2 diabetes · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "HTD1801" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 17 on PubMed

Also in development for T2DM (Type 2 Diabetes Mellitus)

  • ASC30 A1ASC30Phase 35 trials

    Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight

  • RAY1225Phase 35 trials

    Guangdong Raynovent Biotech Co., Ltd · Obesity, T2DM, T2DM (Type 2 Diabetes Mellitus)

  • DWP16001Phase 32 trials

    Daewoong Pharmaceutical Co. LTD. · Type 2 Diabetic Nephropathy, T2DM (Type 2 Diabetes Mellitus)

  • DWC202518Phase 31 trial

    Daewoong Pharmaceutical Co. LTD. · T2DM (Type 2 Diabetes Mellitus)

  • SYH2069group 1, group 2Phase 22 trials

    CSPC Ouyi Pharmaceutical Co., Ltd. · T2DM (Type 2 Diabetes Mellitus), Overweight or Obesity

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.